ClinicalTrials.gg
CompletedNCT02348632Updated Jun 25, 2019Results posted

"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"

A Phase 3 interventional study of JZP-110 in Narcolepsy and Obstructive Sleep Apnea, sponsored by Jazz Pharmaceuticals. Completed at 80 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-06-25.

Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
645
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies in Narcolepsy by Jazz Pharmaceuticals — 1 open to participants now, 1 under way, 1 of them phase 3. Narcolepsy · Jazz Pharmaceuticals.

Enrollment
Largest of 15
645 · median 120
Started
2015
with 2 others
Phase 3
8 of 18
1 open now
Registered
7th of 18
by date

Among the 18 studies in Narcolepsy by Jazz Pharmaceuticals, this one has the largest enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2015, is one of 8 in phase 3, and was the 7th registered.

Narcolepsy

158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.

Browse Narcolepsy studies →

Open to participants now

1 of the 18 studies in Narcolepsy by Jazz Pharmaceuticals is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Narcolepsy by Jazz Pharmaceuticals, or all of them as a file.
02

Study summary

This is a Phase 3 study to assess the long-term safety and maintenance of efficacy of JZP-110 in subjects who have completed Study 14-002, 14-003, 14-004, 15-004, 15-005, ADX-N05 201, or ADX-N05 202.

03

Conditions studied

  • Narcolepsy
  • Obstructive Sleep Apnea
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  1. Subject meets one of the following:

    1. Completed Study 14-002 or 14-003 (Group A)
    2. Completed Study 14-004, 15-004, 15-005, ADX-N05 201 or ADX-N05 202 (Group B)
  2. from 18 to \<45 kg/m2
  3. Consent to use a medically acceptable method of
  4. Willing and able to provide written

Major Exclusion Criteria:

  1. Female subjects who are pregnant, nursing, or lactating
  2. Any other medical, behavioral, or psychiatric disorder other than narcolepsy or OSA that is associated with excessive sleepiness
  3. History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to criteria
  4. Presence of any acutely unstable medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or surgical history that could affect the safety of the subject or interfere with study efficacy or safety assessments, or the ability of the subject to complete the trial per the judgment of the Investigator
  5. History of bariatric surgery within the past year or a history of roux-en-y procedure
  6. Presence or history of significant cardiovascular disease
  7. Use of any over the counter (OTC) or prescription medications that could affect the evaluation of excessive sleepiness
  8. Received an drug other than JZP-110 in the past 30 days or five half-lives (whichever is longer)
  9. History of phenylketonuria (PKU) or history of to phenylalanine-derived products
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
645 participants (actual)

Study arms

  • Other
    75 mg - 300 mg of JZP-110

    Once Daily Dosing

    Drug: JZP-110

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Epworth Sleepiness Scale (ESS) Score

    Change in Epworth Sleepiness Scale (ESS) score during the 2-week randomized withdrawal period. The beginning of the randomized withdrawal period represents efficacy baseline. A negative change from baseline represents improvement in excessive sleepiness. The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. This analysis included treatment group and randomization stratification factor (narcolepsy vs. OSA) as fixed effects. The ESS score at the beginning of the randomized withdrawal period was used as the covariate. The response variable was the change in ESS score from the beginning to the end of 2- week randomized withdrawal period.

    Time frame: Start of randomized withdrawal phase to end of randomized withdrawal (2 weeks)

Secondary outcomes

  1. Subjects Reported as Worse on the Patient Global Impression of Change (PGIc)

    Percentage of subjects reported as worse (minimally worse, much worse, or very much worse) on the PGIc during the 2-week randomized withdrawal period. The beginning of the randomized withdrawal period represents efficacy baseline.

    Time frame: Beginning of randomized withdrawal phase to end of the randomized withdrawal phase (2 weeks)

  2. Subjects Reported as Worse on the Clinical Global Impression of Change (CGIc)

    Subjects reported as worse (very much worse, much worse, and minimally worse) on the CGIc during the 2-week randomized withdrawal period. The beginning of the randomized withdrawal period represents efficacy baseline.

    Time frame: Beginning of randomized withdrawal phase to end of the randomized withdrawal phase (2 weeks)

07

Results

Posted Jun 25, 2019

Participant flow

Open-label Period
Participant flow — Open-label Period
MilestoneJZP-110Placebo
Started6430
Completed4580
Not completed1850
Randomized Withdrawal Period
Participant flow — Randomized Withdrawal Period
MilestoneJZP-110Placebo
Started140142
Completed137141
Not completed31

Outcome measures

PrimaryChange in Epworth Sleepiness Scale (ESS) Score

Change in Epworth Sleepiness Scale (ESS) score during the 2-week randomized withdrawal period. The beginning of the randomized withdrawal period represents efficacy baseline. A negative change from baseline represents improvement in excessive sleepiness. The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. This analysis included treatment group and randomization stratification factor (narcolepsy vs. OSA) as fixed effects. The ESS score at the beginning of the randomized withdrawal period was used as the covariate. The response variable was the change in ESS score from the beginning to the end of 2- week randomized withdrawal period.

Time frame:
Start of randomized withdrawal phase to end of randomized withdrawal (2 weeks)
Reported as:
Least squares mean · points on a scale
Change in Epworth Sleepiness Scale (ESS) Score
points on a scaleJZP-110Placebo
Change in Epworth Sleepiness Scale (ESS) Score1.6 ± 0.415.3 ± 0.41
SecondarySubjects Reported as Worse on the Patient Global Impression of Change (PGIc)

Percentage of subjects reported as worse (minimally worse, much worse, or very much worse) on the PGIc during the 2-week randomized withdrawal period. The beginning of the randomized withdrawal period represents efficacy baseline.

Time frame:
Beginning of randomized withdrawal phase to end of the randomized withdrawal phase (2 weeks)
Reported as:
Number · percentage of subjects
Subjects Reported as Worse on the Patient Global Impression of Change (PGIc)
percentage of subjectsJZP-110Placebo
Subjects Reported as Worse on the Patient Global Impression of Change (PGIc)28.264.5
SecondarySubjects Reported as Worse on the Clinical Global Impression of Change (CGIc)

Subjects reported as worse (very much worse, much worse, and minimally worse) on the CGIc during the 2-week randomized withdrawal period. The beginning of the randomized withdrawal period represents efficacy baseline.

Time frame:
Beginning of randomized withdrawal phase to end of the randomized withdrawal phase (2 weeks)
Reported as:
Number · percentage of subjects
Subjects Reported as Worse on the Clinical Global Impression of Change (CGIc)
percentage of subjectsJZP-110Placebo
Subjects Reported as Worse on the Clinical Global Impression of Change (CGIc)28.763.8

Adverse events

Collected over The Safety Population consisted of all subjects who received at least 1 dose of study medication. Adverse events are reported across the entire study (e.g., the open-label and randomized withdrawal periods combined).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
JZP-1101/643 (0.2%)27/643 (4.2%)269/643 (41.8%)
Placebo0/142 (0%)0/142 (0%)3/142 (2.1%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventJZP-110Placebo
Atrial fibrillationCardiac disorders4/6430/142
AgitationPsychiatric disorders2/6430/142
Hallucination, auditoryPsychiatric disorders2/6430/142
Alcohol poisoningInjury, poisoning and procedural complications2/6430/142
DizzinessNervous system disorders2/6430/142
Cluster headacheNervous system disorders2/6430/142
Abdominal painEar and labyrinth disorders2/6430/142
Deep vein thrombosisVascular disorders1/6430/142
Prostate cancer stage INeoplasms benign, malignant and unspecified (incl cysts and polyps)1/6430/142
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/6430/142
Most frequent other events
Most frequent other events
EventJZP-110Placebo
HeadacheNervous system disorders71/6430/142
NauseaGastrointestinal disorders57/6431/142
NasopharyngitisInfections and infestations54/6431/142
InsomniaPsychiatric disorders51/6431/142
Dry mouthGastrointestinal disorders47/6430/142
AnxietyPsychiatric disorders46/6430/142
Decreased appetiteMetabolism and nutrition disorders32/6430/142
Upper respiratory tract infectionInfections and infestations32/6430/142

Baseline characteristics

Age, Continuous
Age, Continuous(years)Open-label Period
Mean49.31 ± 14.155
Sex: Female, Male
Sex: Female, Male(Participants)Open-label Period
Female306
Male337
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Open-label Period
American Indian or Alaska Native2
Asian15
Native Hawaiian or Other Pacific Islander3
Black or African American109
White506
More than one race8
Unknown or Not Reported0
08

Study locations

80 sites
  • Sleep Disorders Center of Alabama
    Birmingham, Alabama 35213, United States
  • Pulmonary Associates
    Glendale, Arizona 85306, United States
  • Mayo Clinic in Arizona
    Scottsdale, Arizona 85259, United States
  • Preferred Research Partners
    Little Rock, Arkansas 72211, United States
  • UC San Diego Medical Center
    La Jolla, California 92037, United States
  • So Cal Institute For Respiratory Diseases, Inc.
    Los Angeles, California 90048, United States
  • Pacific Sleep Medicine
    Oceanside, California 92054, United States
  • The Research Center of Southern California
    Oceanside, California 92056, United States
  • Stanford University Center for Narcolepsy
    Redwood City, California 94063, United States
  • Pacific Research Network Inc.
    San Diego, California 92103, United States
  • VA San Diego Healthcare System
    San Diego, California 92161, United States
  • Santa Monica Clinical Trials
    Santa Monica, California 90404, United States
  • Critical care Pulmonary & Sleep Associates, LLC
    Lakewood, Colorado 80228, United States
  • MD Clinical
    Hallandale Beach, Florida 33009, United States
  • Oviedo Medical Research, LLC
    Oviedo, Florida 32765, United States
  • Clinical Research Group of St. Petersburg
    Saint Petersburg, Florida 33707, United States
  • Florida Pediatric Research Institute
    Winter Park, Florida 32789, United States
  • Emory Sleep Center
    Atlanta, Georgia 30329, United States
  • NeuroTrials Research Inc.
    Atlanta, Georgia 30342, United States
  • SleepMed of Central Georgia
    Macon, Georgia 31201, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • University of Illinois at Chicago Nursing School
    Chicago, Illinois 60612, United States
  • Rowe Neurology Institute RNI - Lenexa
    Lenexa, Kansas 66214, United States
  • Veritas Clinical Specialties LTD
    Topeka, Kansas 66606, United States
  • Kentucky Research Group
    Louisville, Kentucky 402318, United States
  • Advanced Neurodiagnostic Center
    Metairie, Louisiana 70006, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21224, United States
  • The Center for Sleep & Wake Disorders
    Chevy Chase, Maryland 20815, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Neurocare, Inc.
    Newton, Massachusetts 24590, United States
  • Henry Ford Hospital Sleep Disorders & Research Center
    Detroit, Michigan 48202, United States
  • Clinical Neurophysiology Services
    Sterling Heights, Michigan 48314, United States
  • Minnesota Lung Center
    Edina, Minnesota 55435, United States
  • Sleep Medicine & Research center, St. Lukes Hospital
    Chesterfield, Missouri 63017, United States
  • University of Missouri
    Columbia, Missouri 65201, United States
  • Clayton Sleep Institute
    Saint Louis, Missouri 63143, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • New York University Medical Center
    New York, New York 10016, United States
  • Clinilabs
    New York, New York 10019, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Hickory Research Center
    Hickory, North Carolina 28602, United States
  • Hickory Research Center, ARSM Research, LLC
    Huntersville, North Carolina 28078, United States
  • Raleigh Neurology Associates
    Raleigh, North Carolina 27607, United States
  • PMG Research of Wilmington
    Wilmington, North Carolina 28401, United States
  • Northcoast Clinical Trials Inc.
    Beachwood, Ohio 44122, United States
  • Sleep Management Institute
    Cincinnati, Ohio 45245, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45255, United States
  • Case Western Reserve University
    Cleveland, Ohio 44106, United States
  • Southwest Cleveland Sleep Research Center
    Cleveland, Ohio 44130, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Ohio Sleep Medicine & Neuroscience Institute
    Dublin, Ohio 43017, United States
  • Mercy St. Anne & Mercy St. Charles Sleep Disorders Center
    Toledo, Ohio 43606, United States
  • Center for Sleep and Circadian Neurobiology
    Philadelphia, Pennsylvania 19104, United States
  • UPMC Sleep Medicine Center
    Pittsburgh, Pennsylvania 15213, United States
  • Lowcountry Lung Critical Care
    Charleston, South Carolina 29406, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Sleep Med of South Carolina Clinical Research Solutions
    Columbia, South Carolina 29201, United States
  • FutureSearch Trials of Neurology LP
    Austin, Texas 78731, United States
  • Todd J. Swick
    Houston, Texas 77063, United States
  • Sleep Therapy & Research Center
    San Antonio, Texas 78229, United States
  • EVMS Sleep Medicine
    Norfolk, Virginia 23510, United States
  • American Sleep Medicine
    Vienna, Virginia 22182, United States
  • Swedish Medical Center
    Seattle, Washington 98122, United States
  • London Health Sciences Centre
    London, Ontario N6A 5W9, Canada
  • Niagra Clinical Research
    Niagra Falls, Ontario L2E 7H9, Canada
  • Toronto Sleep Institute
    Toronto, Ontario M4P 1P2, Canada
  • Toronto Psychiatric Research Foundation
    Toronto, Ontario m5K 2A7, Canada
  • Pediatric Sleep Research Inc
    Toronto, Ontario M6J 3S3, Canada
  • CARSM Sleep Laboratory & Clinic
    Montreal, Quebec H4J 1C5, Canada
  • Unesta Research Center
    Tampere, 33200, Finland
  • University of Turku , Sleep Research Centre
    Turku, 20520, Finland
  • CHU de Dijon
    Dijon, 21000, France
  • Grenoble University Hospital
    La Tronche, 38700, France
  • Hospital Roger Salengro
    Lille, 59000, France
  • Universite Paris 5 Hôtel-Dieu
    Paris, 75004, France
  • Hopital Bichat - Claude Bernard
    Paris, 75018, France
  • CHU de Poitiers
    Poitiers, 86000, France
  • Somnolab Dortmund
    Dortmund, 44263, Germany
  • Klinische Forschung Schwerin GmbH
    Schwerin, 19055, Germany
  • Sleep Wake Center SEIN Heemstede
    Heemstede, Noord Holland 2103 SW, Netherlands
09

References and documents

Publications

  • Weaver TE, Pepin JL, Schwab R, Shapiro C, Hedner J, Ahmed M, Foldvary-Schaefer N, Strollo PJ, Mayer G, Sarmiento K, Baladi M, Bron M, Chandler P, Lee L, Malhotra A. Long-term effects of solriamfetol on quality of life and work productivity in participants with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. J Clin Sleep Med. 2021 Oct 1;17(10):1995-2007. doi: 10.5664/jcsm.9384. PubMed 34606437 ↗
  • Schweitzer PK, Strohl KP, Mayer G, Rosenberg R, Chandler P, Baladi M, Lee L, Malhotra A. Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy. J Clin Sleep Med. 2021 Apr 1;17(4):659-668. doi: 10.5664/jcsm.8992. PubMed 33179591 ↗
  • Malhotra A, Shapiro C, Pepin JL, Hedner J, Ahmed M, Foldvary-Schaefer N, Strollo PJ, Mayer G, Sarmiento K, Baladi M, Chandler P, Lee L, Schwab R. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea. Sleep. 2020 Feb 13;43(2):zsz220. doi: 10.1093/sleep/zsz220. PubMed 31691827 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Dec 2017 and a completion of Dec 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2019, 1 year 6 months after primary completion. A results delay was requested in Dec 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2015
First posted
Jan 28, 2015
Start
May 2015
Primary completionActual
Dec 2017
CompletionActual
Dec 2017
Results delay requested
Dec 5, 2018
Results first posted
Jun 25, 2019
Last update
Jun 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02348632
Responsible party
Sponsor
First posted
Jan 28, 2015
Start date
May 2015
Primary completion
Dec 2017
Completion
Dec 2017
Results posted
Jun 25, 2019
Last update
Jun 25, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solriamfetol

Start the discussion